Key Points
- DexCom EVP Michael Brown sold 1,700 shares for $145,316 at an average price of $85.48, reducing his direct ownership by 1.70%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- DexCom reported quarterly EPS of $0.70, beating estimates of $0.61, while revenue rose 13.1% year over year to $1.31 billion. The stock opened at $85.98 and has traded between $54.11 and $92.59 over the past year.
- Analysts maintain a consensus “Buy” rating with an average price target of $92.43, while institutional investors own 97.75% of the company’s shares.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total transaction of $145,316.00. Following the transaction, the executive vice president directly owned 98,185 shares in the company, valued at approximately $8,392,853.80. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Jon Brown also recently made the following trade(s):
- On Tuesday, September 15th, Michael Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $84.04, for a total transaction of $142,868.00.
DexCom Price Performance
DXCM opened at $85.98 on Tuesday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59. The company has a fifty day simple moving average of $87.58 and a 200 day simple moving average of $76.12. The stock has a market cap of $32.45 billion, a P/E ratio of 33.98, a P/E/G ratio of 1.44 and a beta of 1.48.
DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The firm's revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.48 EPS. On average, research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Mather Group LLC. lifted its position in shares of DexCom by 27.7% in the 3rd quarter. Mather Group LLC. now owns 563 shares of the medical device company's stock worth $49,000 after purchasing an additional 122 shares during the period. Elevation Wealth Partners LLC increased its position in shares of DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company's stock valued at $35,000 after buying an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in shares of DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company's stock valued at $77,000 after buying an additional 153 shares during the period. V Square Quantitative Management LLC increased its position in shares of DexCom by 1.8% during the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company's stock valued at $604,000 after buying an additional 172 shares during the period. Finally, Essex Financial Services Inc. raised its stake in DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company's stock worth $204,000 after buying an additional 175 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. BTIG Research raised their price target on DexCom from $90.00 to $96.00 and gave the stock a "buy" rating in a research report on Monday, October 12th. TD Cowen reiterated a "buy" rating and issued a $95.00 price objective on shares of DexCom in a research report on Friday, September 18th. UBS Group set a $96.00 price objective on DexCom and gave the company a "buy" rating in a research report on Tuesday, July 28th. Canaccord Genuity Group set a $90.00 target price on DexCom and gave the stock a "buy" rating in a research note on Monday, August 3rd. Finally, JPMorgan Chase & Co. increased their target price on DexCom from $65.00 to $82.00 and gave the stock a "neutral" rating in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $92.43.
Get Our Latest Stock Analysis on DXCM
About DexCom
(
Get Free Report)
DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.
The company's product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
